Soluble Guanylate Cyclase Stimulator [EPC]

Known as: Soluble Guanylate Cyclase Stimulator 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2016-2016
01220162016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Aims To determine tolerability and the optimal dose regimen of the soluble guanylate cyclase stimulator vericiguat in patients… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2017
2017
AIMS Exploratory assessment of the potential benefits of the novel soluble guanylate cyclase stimulator vericiguat on health… (More)
Is this relevant?
2017
2017
BACKGROUND Pulmonary arterial hypertension (PAH) is a devastating disease and ultimately leads to right heart failure and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 3
  • figure 4
Is this relevant?
2016
2016
This population pharmacokinetics (PK) analysis characterized the PK of the oral soluble guanylate cyclase stimulator riociguat in… (More)
Is this relevant?
2016
2016
Female patients requiring treatment for pulmonary arterial hypertension (PAH) are advised to avoid pregnancy because of the high… (More)
Is this relevant?